Source: Beta | Thursday, 07.09.2017.| 08:21
Highlight an article Print out the news

New medical drugs for HIV and Parkinson's disease to arrive to Serbia

Illustration
Illustration (Photo: OSABEE/shutterstock.com)
The pharmaceutical company Actavis announced yesterday that it would provide the first generic substitute for HIV therapy to patients and the health system of Serbia, leading to considerable savings.

– This is a therapy equally as efficient as the existing one, except that now it will be available at a considerably lower price, which will enable a larger number a HIV patients to be treated using a modern combination of drugs – Actavis says in its press release.

It is added that Actavis would provide the first generic copy of a fixed combination of drugs for Parkinson's disease before the end of the year, reducing the participation cost paid by the patients.

– Thanks to the fact that we are a part of the Teva Group, one of the biggest pharmaceutical companies in the world, we are now able to provide Serbia with a large number of modern and proven medical drugs used in nearly all fields of therapy, under conditions which will enable the healthcare fund and the patients to use a part of the money for other purposes – said Pavle Marjanovic, General Manager of Actavis for Serbia and Montenegro.

He announced that Actavis would also provide four very important medicines for the therapy of hospital patients.

The Leskovac-based medical drug factory Zdravlje is a member of Actavis.
Only logged-in users can comment.
Follow the news, tenders, grants, legal regulations and reports on our portal.
Testiraj besplatno!
Register for our daily business bulletin, which is sent to your email address at the end of each work day.
Full information is available only to commercial users-subscribers and it is necessary to log in.
Test for free!
Testiraj besplatno!
Full information is available to commercial users-subscribers only.
Testiraj besplatno!

Log in to view complete information:
Forgot your password? Click here HERE
For free test use, click HERE